Latest Conference Articles

Discover essential insights and innovative strategies at FMX 2025, featuring key topics like AI in healthcare and advancements in family medicine.

Get a first look at can’t-miss sessions from day 2 of FMX 2025—from vaccines and metabolic health to dementia, women’s care, and AI in family medicine.

From vaccines to reproductive health to AI, here are 16 sessions you won't want to miss at FMX 2025.

Preview the top sessions at the AAFP Family Medicine Experience (FMX) 2025. From vaccines and obesity care to dementia and LGBTQ+ health, here are 10 highlights for family physicians.

Linus Health will demonstrate advances in remote assessment platforms and digital biomarkers of cognitive health that can bring precision medicine to primary care.

This year, the FMX Main Stage presenters will be led by Vivek H Murthy, the 21st US Surgeon General. Learn more about him and the 2 other inspiring guests.

The annual meeting of the American Academy of Family Physicians is a unique chance to choose continuing education on just about any topic a family physician could imagine.

Vaccines for respiratory syncytial virus were found both safe and effective across 100,000 participants and, critically, for older adults and infants.

Missing a first screening mammogram was associated with a 53% greater risk of stage III breast cancer and a 40% higher risk of mortality from the disease.

The study found that although PREVENT-generated risk estimates were more consistent in a broad population, PCE estimates were more accurate in those taking statins.

Corticosteroids following resolution of anaphylaxis should be chosen with clear, clinical rationale and reserved for select children, study authors concluded.

If approved, the nonhormonal drug could offer an important new option for postmenopausal women seeking alternatives to hormone therapy.

The updated prescribing information includes phase 3b BATURA trial results showing a 46% reduction in severe exacerbations in mild asthma vs albuterol.

Most parents support childhood vaccines such as MMR and polio, but skepticism about seasonal and newer shots persists, along with distrust of federal agencies.

A single dose of neffy was effective in nearly 90% of patients treated for anaphylactic reactions during oral food challenge and allergen immunotherapy.

Teresa Lovins, MD, talked with Patient Care about suicidal ideation among patients and then focused on asking her colleagues to make their own mental health a priority.

Family physician Teresa Lovins, MD, explains how primary care clinicians can determine when to manage depression and when urgent referral is needed.

William Schaffner, MD, advises first and foremost to stay away from politics, to acknowledge and normalize patient fear and concern, and to answer quickly and with confidence.

Sarah Sams, MD, emphasizes education, empathy, and proactive communication to support families and protect public health.

If primary care clinicians are to meet the cognitive screening demands that are growing with an aging population, they need the sharpest tools in the box, this expert says.

Bayer's elinzanetant, a potential nonhormonal treatment for menopausal symptoms, awaits FDA approval after a 90-day review extension.

ADA 2025: Dapiglutide showed promising safety and weight loss results in a phase 1b trial, targeting obesity and inflammation with once-weekly dosing.

RAD 2025: Multidisciplinary collaboration at disease-specific meetings drives clinical and therapeutic progress in AD, Dr Yu told Patient Care.

Dermatologists aren't trained in mental health but once in practice they need to have a deep appreciation for the emotional impact of diseases like AD and a low bar for mental health referral.

At RAD 2025, Dr Yu shared hopes for more real-world data and targeted treatment approaches for chronic hand eczema.

RAD 2025: Yale dermatologist Mona Shahriari, MD, urged primary care clinicians to refer patients with AD who don't improve to prevent cumulative emotional burden.

RAD 2025: Expert insights on the psychosocial burden of AD, flexible dosing, and cross-specialty collaboration in pediatric care.

RAD 2025: Johann Gudjonsson, MD, PhD, on investigational AD treatments, including anti–IL-31 receptor antibodies, anti–IL-13 treatments, IL-4 receptor blockers, JAK inhibitors, and new topical agents.

RAD 2025: Brad Glick, DO, MPH, discusses the intensity of TSW symptoms and cautions against assuming there is mental health disturbance at work.

Johann Gudjonsson, MD, discusses how OX-40/OX-40L signaling drives immune activation in AD and its emerging role as a genetic and therapeutic target.